Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• HER2 over-expression is a key driver of aggressive breast cancer, correlating with poor prognosis.
• Trastuzumab, a HER2-targeted therapy, significantly improves outcomes in first-line treatment but resistance develops.
• Mechanisms of resistance limit trastuzumab efficacy in later treatment lines, necessitating alternative strategies.

Purpose of the Study:

• To review the clinical utility of continuing trastuzumab beyond progression in HER2-positive breast cancer.
• To explore emerging therapeutic strategies for overcoming trastuzumab resistance in metastatic breast cancer.

Main Methods:

• Literature review of clinical trials and studies on HER2-positive breast cancer treatment.
• Analysis of mechanisms of resistance to trastuzumab therapy.
• Evaluation of novel therapeutic agents targeting HER2 and resistance pathways.

Main Results:

• Continuing trastuzumab beyond progression shows clinical utility in select patients.
• Multiple resistance mechanisms contribute to treatment failure.
• Several novel therapeutic classes are under investigation for trastuzumab-resistant disease.

Conclusions:

• Trastuzumab remains a cornerstone in HER2-positive breast cancer, with ongoing research into its use beyond progression.
• Overcoming resistance requires a multi-faceted approach, including novel targeted therapies.
• Future treatments may involve tyrosine kinase inhibitors, antibody-drug conjugates, and pathway-specific inhibitors.